Robert Spooner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2199677/publications.pdf

Version: 2024-02-01

28 papers 1,098 citations

394421 19 h-index 28 g-index

28 all docs 28 docs citations

times ranked

28

1231 citing authors

#	Article	IF	CITATIONS
1	Specific Rab GTPase-activating proteins define the Shiga toxin and epidermal growth factor uptake pathways. Journal of Cell Biology, 2007, 177, 1133-1143.	5.2	130
2	Gene-Directed Enzyme Prodrug Therapy. Bioconjugate Chemistry, 1998, 9, 4-22.	3.6	88
3	A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy. Nature Biotechnology, 1997, 15, 1373-1377.	17.5	85
4	Ricin Trafficking in Cells. Toxins, 2015, 7, 49-65.	3.4	73
5	Cytosolic chaperones influence the fate of a toxin dislocated from the endoplasmic reticulum. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17408-17413.	7.1	72
6	Internalized Pseudomonas Exotoxin A can Exploit Multiple Pathways to Reach the Endoplasmic Reticulum. Traffic, 2006, 7, 379-393.	2.7	65
7	Ricin Trafficking in Plant and Mammalian Cells. Toxins, 2011, 3, 787-801.	3.4	59
8	Regressions of Established Breast Carcinoma Xenografts by Carboxypeptidase G2 Suicide Gene Therapy and the Prodrug CMDA Are Due to a Bystander Effect. Human Gene Therapy, 2000, 11, 285-292.	2.7	50
9	Retrograde transport of toxins across the endoplasmic reticulum membrane. Biochemical Society Transactions, 2003, 31, 1260-1262.	3.4	49
10	LG186: An Inhibitor of GBF1 Function that Causes Golgi Disassembly in Human and Canine Cells. Traffic, 2010, 11, 1537-1551.	2.7	45
11	Self-Immolative Nitrogen Mustard Prodrugs for Suicide Gene Therapy. Journal of Medicinal Chemistry, 1998, 41, 5297-5309.	6.4	42
12	Self-Immolative Anthracycline Prodrugs for Suicide Gene Therapy. Journal of Medicinal Chemistry, 1999, 42, 2485-2489.	6.4	41
13	A Human Embryonic Kidney 293T Cell Line Mutated at the Golgi α-Mannosidase II Locus. Journal of Biological Chemistry, 2009, 284, 21684-21695.	3.4	35
14	Toxin entry and trafficking in mammalian cellsâ [†] t. Advanced Drug Delivery Reviews, 2006, 58, 1581-1596.	13.7	33
15	Activation of the xylDLEGF promoter of the TOL toluene-xylene degradation pathway by overproduction of the xylS regulatory gene product. Journal of Bacteriology, 1987, 169, 3581-3586.	2.2	31
16	Eeyarestatin 1 Interferes with Both Retrograde and Anterograde Intracellular Trafficking Pathways. PLoS ONE, 2011, 6, e22713.	2.5	31
17	Simple oxidation of pyrimidinylhydrazones to triazolopyrimidines and their inhibition of Shiga toxin trafficking. European Journal of Medicinal Chemistry, 2010, 45, 275-283.	5.5	26
18	Cytosolic Entry of Shiga-Like Toxin A Chain from the Yeast Endoplasmic Reticulum Requires Catalytically Active Hrd1p. PLoS ONE, 2012, 7, e41119.	2.5	21

#	Article	IF	CITATION
19	Immunotoxins: status and prospects. Trends in Biotechnology, 1990, 8, 189-193.	9.3	19
20	Appropriate subcellular localisation of prodrug-activating enzymes has important consequences for suicide gene therapy. International Journal of Cancer, 2001, 93, 123-130.	5.1	17
21	Construction, characterisation and kinetics of a single chain antibody recognising the tumour associated antigen placental alkaline phosphatase. British Journal of Cancer, 1993, 68, 738-742.	6.4	16
22	Construction, expression and characterisation of a single chain anti-tumour antibody (scFv)-EL-2 fusion protein. Annals of Oncology, 1995, 6, 945-947.	1.2	12
23	Fine tuning Exo2, a small molecule inhibitor of secretion and retrograde trafficking pathways in mammalian cells. Molecular BioSystems, 2010, 6, 2030.	2.9	12
24	An Exo2 Derivative Affects ER and Golgi Morphology and Vacuolar Sorting in a Tissueâ€Specific Manner in <i>Arabidopsis</i> . Traffic, 2011, 12, 1552-1562.	2.7	12
25	RNAi Screening of Drosophila (Sophophora) melanogaster S2 Cells for Ricin Sensitivity and Resistance. Journal of Biomolecular Screening, 2011, 16, 436-442.	2.6	12
26	A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs. British Journal of Cancer, 2003, 88, 1622-1630.	6.4	11
27	Immunotoxins: properties, applications and current limitations. Advanced Drug Delivery Reviews, 1988, 2, 297-318.	13.7	7
28	Expression of immunoglobulin heavy chain-ricin a chain fusions in mammalian cells. Molecular Immunology. 1994, 31, 117-125.	2,2	4